janssen_latest_logo_on_sign_closer

Janssen to stop fulranumab development in osteoarthritis pain

pharmafile | April 1, 2016 | News story | Medical Communications, Research and Development, Sales and Marketing Amgen, Janssen 

Janssen says it is discontinuing Phase III development for fulranumab in osteoarthritis pain.

The J&J company says the decision is based on “strategic portfolio prioritisation”, as opposed to concerns over the safety of the drug – which belongs to an experimental class of non-opioid biological medicines called anti-nerve growth factor compounds.

Janssen is terminating its license with Amgen fulranumab and is returning all program rights back to Amgen. The two signed a licensing agreement in 2008.

Joel Levy

Related Content

Amgen opens new biomanufacturing facility in Ohio, US

Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. …

GSK enters agreement for license for JNJ-3089 for development of bepirovirsen

GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen …

Janssen and Sanofi enter agreement for potential vaccine programme

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …

Latest content